Cargando…

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki

Detalles Bibliográficos
Autores principales:	Hashimoto, Yaeko, Suzuki, Takuji, Hashimoto, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985059/ https://www.ncbi.nlm.nih.gov/pubmed/35388183 http://dx.doi.org/10.1038/s41380-022-01546-2

Ejemplares similares

Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2009)

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
por: Albayrak, Yakup, et al.
Publicado: (2013)

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2010)

A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
por: Albayrak, Yakup, et al.
Publicado: (2019)

Sigma-1 Receptor Agonist Fluvoxamine Ameliorates Fibrotic Response of Trabecular Meshwork Cells
por: Hodrea, Judit, et al.
Publicado: (2023)

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP(3) Receptors and Cellular Signaling Pathways
por: Nishimura, Tomoko, et al.
Publicado: (2008)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor
por: Omi, T, et al.
Publicado: (2014)

Causes of Trauma in Pregnant Women Referred to Shabih-Khani Maternity Hospital in Kashan
por: Mesdaghinia, Elaheh, et al.
Publicado: (2012)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

PT576. Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.
por: Kudo, Takashi
Publicado: (2016)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report
por: Kishimoto, Akira, et al.
Publicado: (2010)

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
por: Hashimoto, Kenji
Publicado: (2021)

Potential Role of the Sigma-1 Receptor Chaperone in the Beneficial Effects of Donepezil in Dementia with Lewy Bodies
por: Hashimoto, Kenji
Publicado: (2013)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32–4
por: Jain, Amit, et al.
Publicado: (2021)

Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder
por: Tadokoro, Shigenori, et al.
Publicado: (2011)

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP(3) Receptors
por: Ishima, Tamaki, et al.
Publicado: (2012)

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
por: Papadopoulos, Konstantinos, et al.
Publicado: (2023)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Reissuing the sigma receptors for SARS-CoV-2
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2020)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Comment on: Vascular cell adhesion molecule-1 in rheumatoid arthritis
por: Jawad, Ali S.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6hu14in52qt6d06p9rk0dplqe